<i>TP53</i>-mutated acute myeloid leukemia: how can we improve outcomes?

Abstract

Abstract Despite advances in the treatment paradigm of patients with acute myeloid leukemia (AML), TP53-mutated AML represents a molecular subgroup that has failed to improve, with an overall survival of ∼6 months that is independent of age and fitness. Notably, there has been significant elucidation in understanding the biology of the disease and key advancements in the classification and prognostication of these patients. International collaborative efforts for novel clinical interventions are urgently needed to change the standard of care.